May 14, 2020 4:05pm EDT NeuBase Therapeutics Reports Financial Results for the Second Fiscal Quarter of 2020
Apr 30, 2020 4:05pm EDT NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apr 28, 2020 9:44am EDT NeuBase Therapeutics Announces Pricing of $31,500,000 Public Offering of Common Stock
Mar 31, 2020 7:00am EDT NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL™ Platform
Mar 26, 2020 4:05pm EDT NeuBase Therapeutics Reports Financial Results for the First Fiscal Quarter of 2020
Feb 21, 2020 4:50pm EST NeuBase Therapeutics Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Dec 02, 2019 8:00am EST NeuBase Therapeutics Wins The Scientist’s Top 10 Innovations of 2019 Award for its Janus Base Technology